IGF-IR and its inhibitors in gastrointestinal carcinomas

Xiao Hong Bao, Yoshio Nomoto, Hui Fang Hao, Nobuyuki Watanabe, Kazufumi Sakurama, Kazuhiro Noma, Takayuki Motoki, Yasuko Tomono, Takuya Fukazawa, Yasuhiro Shirakawa, Tomoki Yamatsuji, Junji Matsuoka, Munenori Takaoka

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

The type I insulin-like growth factor receptor (IGF-IR) and its associated signaling system play a significant role in tumorigenesis, tumor survival and progression, and cancer therapeutic resistance, and thus has provoked great interest as a promising target for cancer treatment. In this report we present the role of IGF-IR in gastrointestinal carcinomas whose pathology has been identified as tightly correlated with an abnormal expression and activation of IGF-IR. Reported data from experimental studies suggest the feasibility of targeted IGF-IR therapy in gastrointestinal carcinomas. Many types of inhibitors against IGF-IR have been developed. Inhibitors with anti-IGF-IR monoclonal antibodies and tyrosine kinase inhibitors currently undergoing preclinical and clinical evolution are also reviewed.

Original languageEnglish
Pages (from-to)195-201
Number of pages7
JournalOncology Letters
Volume1
Issue number1
DOIs
Publication statusPublished - Jan 1 2010

    Fingerprint

Keywords

  • Cancer therapy
  • Gastrointestinal carcinoma
  • Monoclonal antibody
  • Type I insulin-like growth factor receptor
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Bao, X. H., Nomoto, Y., Hao, H. F., Watanabe, N., Sakurama, K., Noma, K., Motoki, T., Tomono, Y., Fukazawa, T., Shirakawa, Y., Yamatsuji, T., Matsuoka, J., & Takaoka, M. (2010). IGF-IR and its inhibitors in gastrointestinal carcinomas. Oncology Letters, 1(1), 195-201. https://doi.org/10.3892/ol_00000036